<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084565</url>
  </required_header>
  <id_info>
    <org_study_id>FCCC-03035</org_study_id>
    <secondary_id>CDR0000365459</secondary_id>
    <nct_id>NCT00084565</nct_id>
  </id_info>
  <brief_title>Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer</brief_title>
  <official_title>Phase II Study of the Activity of Weekly Paclitaxel, Topotecan Plus Oral Estramustine Phosphate in Metastatic Hormone-Refractory Prostate Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as paclitaxel, topotecan, and estramustine, work&#xD;
      in different ways to stop tumor cells from dividing so they stop growing or die. Giving more&#xD;
      than one chemotherapy drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving paclitaxel, topotecan, and&#xD;
      estramustine together works in treating patients with metastatic hormone therapy-refractory&#xD;
      prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the objective response rate in patients with metastatic hormone-refractory&#xD;
           prostate cancer treated with paclitaxel, topotecan, and estramustine.&#xD;
&#xD;
        -  Determine the progression-free and overall survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the frequency and number of circulating tumor cells in patients before and&#xD;
           after treatment with this regimen and at disease progression.&#xD;
&#xD;
        -  Determine the microtubule morphology, β-tubulin isotype pattern, apoptotic markers, and&#xD;
           metaphase chromosome alignment in circulating tumor cells in patients before and after&#xD;
           treatment with this regimen and at disease progression.&#xD;
&#xD;
      OUTLINE: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15; topotecan IV over&#xD;
      30 minutes on days 2, 9, and 16; and oral estramustine twice daily on days 1 and 2 of course&#xD;
      1 and on days 0-2, 7-9, and 14-16 of all subsequent courses. Courses repeat every 28 days in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18-38 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was never activated at Fox Chase Cancer Center.&#xD;
  </why_stopped>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estramustine phosphate sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate gland&#xD;
&#xD;
               -  Progressive metastatic disease (e.g., bone, pelvic mass, lymph node, liver or&#xD;
                  lung metastases)&#xD;
&#xD;
               -  Radiologic evidence of hydronephrosis alone dose not constitute metastatic&#xD;
                  disease&#xD;
&#xD;
          -  Failed prior primary hormonal therapy (e.g., estrogen therapy, luteinizing&#xD;
             hormone-releasing hormone blocker and flutamide) or bilateral orchiectomy&#xD;
&#xD;
               -  Patients previously treated with flutamide or bicalutamide must have evidence of&#xD;
                  disease progression i.e., increasing Prostate-Specific Antigen (PSA)&#xD;
&#xD;
          -  PSA level ≥ 10 ng/mL if bone metastases only are present (i.e., lacking measurable&#xD;
             soft tissue disease)&#xD;
&#xD;
          -  No elevated serum acid phosphatase or PSA level as the only evidence of disease&#xD;
&#xD;
          -  No carcinomatous meningitis or brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  White Blood Cell (WBC) ≥ 4,000/mm^3 OR&#xD;
&#xD;
          -  Granulocyte count ≥ 2,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Serum Glutamic-Oxaloacetic Transaminase(SGOT) and Serum Glutamic-Pyruvic Transaminase&#xD;
             (SGPT) ≤ 2 times normal&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  History of deep venous thrombosis allowed provided patients are maintained on&#xD;
             therapeutic anticoagulation therapy&#xD;
&#xD;
          -  No active angina pectoris&#xD;
&#xD;
          -  No New York Heart Association class II-IV heart disease&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No thrombosis within the past 3 months&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other concurrent serious medical illness that would preclude study participation&#xD;
&#xD;
          -  No other malignancy within the past 3 years except curatively treated basal cell or&#xD;
             squamous cell skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior flutamide&#xD;
&#xD;
          -  At least 8 weeks since prior bicalutamide&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  No prior cytotoxic therapy for prostate cancer&#xD;
&#xD;
          -  No concurrent milk, milk products, antacids, calcium-containing drugs, or food during&#xD;
             estramustine administration&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary R. Hudes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>adenocarcinoma of the prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Estramustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

